Around 50 million people have dementia. The WHO predicts this number will triple by 2050. Advancing our understanding of the fundamental basis for nervous system abnormalities and finding new and effective treatments are paramount.

At Cerba Research, top scientists and industry-leading laboratories drive the development of more advanced biomarker strategies along with custom assays and on-target protocol advice to accelerate your clinical development project.

Patients screened 9,813 Patients screened
Sites 1,819 Sites
Countries 41 Countries

Our Neurology Trials

34%

Alzheimer’s disease

21%

Schizophrenia

40%

FDA approvals

From Alzheimer’s biomarkers to pain studies, we’ve got you covered

We offer a variety of capabilities to help you investigate neurological disorders: